Immunotherapy approach to Alzheimer's studied in fly models
News Mar 28, 2014
Developing treatments that slow, if not halt, the neuronal loss and cognitive decline of Alzheimer's disease (AD) has proven to be a challenge. Among the scientists who have taken on that challenge are researchers at the University of Florida's McKnight Brain Institute in Gainesville, using the fruit fly Drosophila melanogaster as a model. Their results have been reported at the Genetics Society of America's 55th Annual Drosophila Research Conference currently taking place in San Diego, CA until March 30.
The scientists are investigating passive immunotherapy, one of the most promising approaches to blocking the amyloid-β42 (Aβ42) peptide, the main component of the amyloid plaques that damage the brain cells of patients with AD.
Monoclonal antibodies, the cornerstone of immunotherapy, do not easily penetrate the tightly packed cells of the blood–brain barrier. As alternatives to full antibodies, the University of Florida scientists generated transgenic flies expressing two anti-Aβ single chain variable fragments (scFv), known as scFv9 and scFv42.2.
Drosophila flies genetically modified to express human Aβ42 also co-expressed either scFv9 or scFv42.2. Each treatment reduced the loss of photoreceptor neurons due to Aβ42 toxicity and improved the insects' eye morphology. In addition, the flies' mushroom bodies, the brain structures involved in olfactory learning and memory, were protected.
Administering both scFv9 and scFv42.2 to the flies produced a synergistic protective activity, which suggests that both scFvs can simultaneously target different Aβ42 epitopes, the scientists said. This is the first time that two antibodies targeting different regions of Aβ42 have shown synergistic activities, thanks to the experimental flexibility of Drosophila.
In addition to immunotherapy, the scientists investigated the protective effects of a laboratory engineered secreted Heat shock protein 70 (secHsp70) on flies whose brain cells were accumulating Aβ42 extracellularly. Hsp70 is a chaperone that prevents and reverts protein misfolding but is primarily located inside the cell. In flies treated with extracellular secHsp70, the eyes were perfectly organized, cell death was reduced, calyces in the mushroom bodies were preserved, and locomotor function was improved.
The researchers determined that secHsp70 interacted directly with Aβ42 without affecting Aβ42 accumulation and aggregation in the flies' brains. Thus, the protective activity of secHsp70 may be mediated by stable binding to toxic Aβ42 species. This study is a new approach to broadly target amyloids outside the cell and block their ability to attack the surrounding neurons, the scientists said.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Handedness Affects Happiness in Mental Health TreatmentNews
Radical new model of emotion in the brain suggests current treatment for the most common mental health problems could be ineffective or even detrimental to about 50 percent of the population.READ MORE